Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diffuse large B-cell lymphoma (DLBCL)
Biotech
Allogene reports patient death tied to mAb in CAR-T pivotal trial
Given the patient death, the company is dropping the monoclonal antibody called ALLO-647 completely, CEO David Chang told Fierce.
Gabrielle Masson
Aug 1, 2025 8:30am
Merck takes middle dose of ROR ADC forward into phase 3
May 30, 2025 9:51am
Merck ADC RORs into phase 3 with 100% complete response rate
Dec 9, 2024 5:03am
Regeneron seeks clarity on confirmatory trials after FDA hurdle
Mar 29, 2024 5:00am
ASH: Regeneron’s near-approval bispecific shines again
Dec 11, 2023 5:25am
Cancer biotech IMV hunts for a deal as its cash clock ticks down
Mar 16, 2023 8:28am
